Showing results (111-120 of 178) with videos related to

Sort By:
Pageof 18
Journal of Affective Disorders|February 19, 2026
Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 studyShiny Sachdeva, Victor W Li, Trisha Chakrabarty, et al.
The Journal of Clinical Psychiatry|November 14, 2019
Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled TrialMichael E Thase, Sagar V Parikh, Anthony J Rothschild, et al.
BMC Psychiatry|December 29, 2019
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBoadie W Dunlop, Sagar V Parikh, Anthony J Rothschild, et al.
The Journal of Clinical Psychiatry|June 20, 2020
Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 ReportRudolf Uher, Benicio N Frey, Lena C Quilty, et al.
Molecular Psychiatry|June 27, 2022
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysisGustavo C Medeiros, Todd D Gould, William L Prueitt, et al.
Psychiatry Research|December 28, 2020
Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depressionAnthony J Rothschild, Sagar V Parikh, Daniel Hain, et al.
CNS Spectrums|May 23, 2023
Pro-inflammatory markers are associated with response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 reportM Ishrat Husain, Jane A Foster, Brittany L Mason, et al.
Psychiatry Research|January 5, 2022
Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorderSagar V Parikh, Rebecca A Law, Daniel T Hain, et al.
Translational Psychiatry|August 22, 2021
Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant responseLaura M Fiori, Massimiliano Orri, Zahia Aouabed, et al.
Pharmacopsychiatry|July 6, 2022
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) StudyHelena K Kim, Gwyneth Zai, Daniel J Müller, et al.
Pageof 18